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Abstract
Background: Human papillomavirus 16 (HPV-16) L1 protein has the capacity to self-assemble into capsomers or
virus-like particles (VLPs) that are highly immunogenic, allowing their use in vaccine production. Successful
expression of HPV-16 L1 protein has been reported in plants, and plant-produced VLPs have been shown to be
immunogenic after administration to animals.
Results: We investigated the potential of HPV-16 L1 to act as a carrier of two foreign epitopes from Influenza A
virus: (i) M2e2-24, ectodomain of the M2 protein (M2e), that is highly conserved among all influenza A isolates, or (ii)
M2e2-9, a shorter version of M2e containing the N-terminal highly conserved epitope, that is common for both M1
and M2 influenza proteins. A synthetic HPV-16 L1 gene optimized with human codon usage was used as a
backbone gene to design four chimeric sequences containing either the M2e2-24 or the M2e2-9 epitope in two
predicted surface-exposed L1 positions. All chimeric constructs were transiently expressed in plants using the
Cowpea mosaic virus-derived expression vector, pEAQ-HT. Chimeras were recognized by a panel of linear and
conformation-specific anti HPV-16 L1 MAbs, and two of them also reacted with the anti-influenza MAb. Electron
microscopy showed that chimeric proteins made in plants spontaneously assembled in higher order structures,
such as VLPs of T = 1 or T = 7 symmetry, or capsomers.
Conclusions: In this study, we report for the first time the transient expression and the self-assembly of a chimeric
HPV-16 L1 bearing the M2e influenza epitope in plants, representing also the first record of a successful expression
of chimeric HPV-16 L1 carrying an epitope of a heterologous virus in plants. This study further confirms the
usefulness of human papillomavirus particles as carriers of exogenous epitopes and their potential relevance for
the production in plants of monovalent or multivalent vaccines.
Background
Human papillomaviruses (HPVs) are non-enveloped
tumour DNA viruses about 55 nm in diameter with a
double-stranded circular genome of approximately 8 kb
[1]. HPVs are the cause of approximately 5% of all can-
cers [2]. High risk HPVs, of which HPV-16 is the most
prevalent, are responsible not only for causing cervical
cancer in women [3] but also anogenital, head and neck
tumours in men and women [4,5].
The major structural protein of HPV is the L1 capsid
protein that can spontaneously self-assemble in vivo and
in vitro to form capsomers and virus-like particles
(VLPs) that are highly immunogenic [6,7]. L1 can form
two types of VLPs, an icosahedral lattice with a T = 7
symmetry, composed of 72 pentamers which is morpho-
logically identical to the native virions and a smaller T =
1 particle composed of 12 L1 pentamers [8,9]. The
structure of the HPV16 T = 1 particle has been solved
by crystallography. The L1 protein has a jellyroll b sand-
wich structure formed by conserved sequences with
additional hypervariable loops protruding towards the
outer surface of the capsid [9]. The three C-terminal
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exposed and their inter-capsomeric reactions influence
VLP formation. The deletion of the full h4 has no
impact on capsomer assembly, but prevents the forma-
tion of either T = 1 or T = 7 VLPs [10,11].
Recently prophylactic vaccines against HPV-16 have
appeared on the market. These are composed of L1-
based VLPs made in insect or yeast cells. Spontaneous
assembly of HPV-16 L1 protein into VLPs has also been
achieved in plants [12-14]. Plant-produced VLPs were
immunogenic when administered to animals [15],
further justifying continuing research into the use of
plants for producing heterologous proteins for vaccine
use. The HPV-16 L1 protein can assemble into VLPs in
non-plant expression systems not only in its native
form, but also in chimeric forms [16]; expressing the
P1A peptide derived from the P815 tumour-associated
antigen [17], an epitope of Human immunodeficiency
virus type 1 [18], a short epitope of the hepatitis B core
antigen [19], a neutralization epitope of the L2 minor
capsid protein of HPV-6 and -16 [20], and a neutralizing
epitope of Human respiratory syncytial virus (RSV) [21].
Chimeric VLPs have also been produced in transgenic
and transplastomic plants [22-25].
Serological characterization of HPV-16 L1 particles
has been carried out using monoclonal antibodies
(MAbs) that recognize either linear or conformational
surface-exposed epitopes. Amino acid (aa) residues 50,
2 6 6a n d2 8 2o fL 1a r ec r u c i a lf o rr e c o g n i t i o nb yt h e
conformation-specific and neutralizing MAbs H16:V5
and H16:E70 [26]. MAbs H16:7E, H16:9A, and H16:U4
recognize conformational epitopes which are not yet
fully mapped (unidentified epitope within the aa region
1-173, for the first two MAbs, and aa 172-505 for the
last MAb) [27]. Linear epitopes are recognized by MAbs
H16:I23 (aa 111-130), H16:J4 (aa 261-280), and H16:D9
(unidentified epitope) [28]. These MAbs are fundamen-
tal to investigate the use of HPV-16 L1 as carrier, since
they provide information of the intactness and the stabi-
lity of L1-based structures.
For the purpose of expressing an HPV-16 L1-based
scaffold in plants that can be easily engineered to carry
foreign epitopes, we constructed a synthetic L1ΔC22
gene. To investigate the impact of the presence of a for-
eign epitope on VLP assembly and conformation, we
designed four different synthetic genes encoding the L1
protein where two different L1 regions were substituted
by either a 23-aa or a 8-aa epitope from the ectodomain
of the M2 protein (M2e) of Influenza A virus.T h ec h i -
meric L1 proteins generated were tested for their ability
to form T = 1 or T = 7 particles, and characterized by
their reactivity towards a panel of linear and conforma-
tion-specific anti HPV-16 L1 MAbs.
Results
Gene synthesis, cloning and protein structure modelling
A synthetic L1ΔC22 gene lacking the 3’-terminal domain
reported to code for a nuclear localization signal [29]
was designed, that contained unique restriction sites
located within nucleotide regions encoding the struc-
tural helices and b-sheets (Figure 1A). Restriction sites
at the 5’- and 3’-terminus were introduced for appropri-
ate cloning into the non-replicating plant expression
vector pEAQ-HT (Figure 1B) [30]. Additionally, this
gene sequence was optimized with human codon usage,
as it was previously shown that this increased HPV-16
L1 yield in plants [12,14]. The L1ΔC22 gene sequence
w a su s e da sab a c k b o n et og e n e r a t ef o u rc h i m e r i cv a r -
iants (Table 1 and Figure 2) containing two different
M2e influenza epitopes: M2e2-24 or M2e2-9 (aa 2-24 and
aa 2-9 of the M2e protein, respectively) that replaced L1
sequences predicted to form either h4 (chimeras
ChiM2e2-24_h4 and ChiM2e2-9_h4, respectively), or the
coil region connecting h4 and b sheet J (hereinafter
“coil”) (chimeras ChiM2e2-24_c and ChiM2e2-9_c,
respectively). L1ΔC22 and chimeric genes were cloned
in pEAQ-HT, and after sequencing control, all con-
structs were transformed into Agrobacterium
tumefaciens.
Protein structure predictions revealed that all chimeras
folded in a way that resembled the crystallographic
structure of the native L1 protein [9], but we observed
that chimeras with the shorter version of the M2e epi-
tope replacing either h4 or the coil region were more
similar than those carrying the longer M2e epitope ver-
sion (Figure 3).
Expression of L1ΔC22 and chimeric constructs
To determine whether L1ΔC22 and its chimeric variants
could be transiently expressed in Nicotiana benthami-
ana, we analysed tissue extracts from agroinfiltrated
leaves by western blot using the MD2H11 MAb (kindly
provided by M. Müller, German Cancer Research Cen-
ter, Heidelberg, Germany) which is specific for the
HPV16-L1 protein. L1ΔC22 and chimeric gene variants
expressed an HPV-16 L1 monomer of the expected size
of 55 kDa, with the exception of ChiM2e2-24_h4 that
migrated slightly slower and showed the strongest signal
(Figure 4A). No evident proteolysis was observed with
L1ΔC22 or with chimeric L1 protein extracts. Expres-
sion of L1ΔC22 and chimeras was confirmed with
CAMVIR-1, another anti-HPV16 L1 MAb (data not
shown). Testing for the presence of influenza epitopes
using the anti-M2 14C2 MAb (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) resulted in the recognition of the
longer epitope (M2e2-24) in either h4 and the coil posi-
tion, while this antibody was unable to detect constructs
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concluded that all synthetic chimeric constructs were
successfully expressed and that two of them expressed
also influenza epitopes. Further step was to determine if
chimeras were able to preserve an appropriate confor-
mation necessary to form assembled protein structures.
Characterization of L1ΔC22 and chimeric constructs by
capture-ELISA
All the linear and conformation-dependent MAbs
reacted with L1ΔC22 and chimeric constructs from
agroinfiltrated leaf extracts when analysed by capture
ELISA (Figure 5). The highest L1 value was obtained six
days post-agroinfiltration i nat i m ec o u r s ea n a l y s i so f
ten days (data not shown). Binding of conformation-spe-
cific MAbs with all L1-based chimeric protein con-
structs indicated that they aggregated in higher order
structures, such as capsomers, or VLPs in either T = 1
or T = 7 form. Recognition of chimeras by these confor-
mation-specific MAbs confirmed not only their expres-
sion in plants, but also proved that their self-assembly
ability (into capsomer or VLP) was not abolished by the
substitution of h4 or coil surface-exposed L1 regions
with the foreign influenza epitopes. Among all chimeras,
ChiM2e2-24_h4 showed the highest binding affinity with
the conformation-dependent neutralizing MAbs (H16:
V5 and H16:E70).
The estimated yield of L1ΔC22 and chimeric proteins
accumulated in agroinfiltrated leaves was measured six
days post-agroinfiltration (Table 2). L1 quantification
was calculated by capture-ELISA using the H16:J4 MAb
which recognizes a linear epitope in both monomeric
and assembled structures and the H16:V5 conforma-
tion-specific MAb which binds only to assembled struc-
tures. The highest L1 yield was obtained for ChiM2e2-
24_h4 with both MAbs (120 and 78 mg/kg plant mate-
rial, with H16:J4 and H16:V5, respectively; correspond-
ing to approximately 3.9% of total soluble proteins,
TSP), followed by ChiM2e2-24_c (45 mg/kg plant mate-
rial, with both MAbs; corresponding to 1.5% TSP).
ChiM2e2-24_h4 accumulated also higher yield then the
L1ΔC22 backbone protein, suggesting that the substi-
tuted amino-acid sequence had a positive impact on
protein stability. On the other hand, the two chimeras
Figure 1 Schematic representation of the synthetic L1ΔC22 gene and of the expressing cassettes made in the pEAQ-HT vector.( a )
Synthetic L1ΔC22 gene. Unique restriction sites with nucleotide positions in brackets are shown. Structural helices and b-sheets are indicated as
cylinders or white boxes, respectively. The h4 or the coil region connecting h4 and b-J where the substitutions with the M2e epitopes were
made are shown in gray or black, respectively. (b) pEAQ-HT expression cassette containing the L1ΔC22 gene, under the control of the Cauliflower
mosaic virus 35S promoter (CaMV-P), 5’ and 3’ non-translated regions (NTR) of Cowpea mosaic virus RNA-2, and nopaline synthase terminator
(Nos-T). RB and LB: right and left borders of T-DNA, respectively; P19: suppressor of gene silencing; CaMV-T: CaMV terminator; NPT: neomycin
phosphotransferase.
Table 1 Chimeric constructs with the L1ΔC22 regions deleted and the influenza epitopes inserted.
Chimeric variant L1ΔC22 modifications
Structural function Deleted sequence aa position Inserted Influenza M2e sequence aa position
ChiM2e2-24_h4 h4 LEDTYRFVTQAI 440-451 SLLTEVETPTRNEWECKCIDSSD 440-462
ChiM2e2-9_h4 h4 LEDTYRFVTQAI 440-451 SLLTEVET 440-447
ChiM2e2-24_c coil between h4 and b-J HTPPAPKEDDPLKK 456-469 SLLTEVETPTRNEWECKCIDSSD 456-478
ChiM2e2-9_c coil between h4 and b-J HTPPAPKEDDPLKK 456-469 SLLTEVET 456-463
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lated at lower amount compared to both L1ΔC22 and
chimeras having longer substitution. The greater differ-
ence observed between H16:J4 and H16:V5 in the case
of L1ΔC22 and ChiM2e2-24_h4 suggested that mono-
meric L1 protein was also accumulating, beside the
assembled species.
Electron microscopy of purified L1ΔC22 and chimeric
constructs
To investigate the structureo fV L P sa n d / o rc a p s o m e r s
formed by L1ΔC22 and chimeras in plants, we carried
out Cs2SO4 density gradient and further analysed the
fractions obtained by electron microscopy. A begomo-
virus purification protocol [31] adopted for purifying
VLPs of other papillomaviruses (Matić and Noris,
unpublished results) was successfully employed to purify
HPV-16 L1 particles. In L1ΔC22 preparations, spherical
T = 7 VLPs of expected size of 55 nm were formed; in
addition small VLPs with probable T = 1 symmetry of
a b o u t3 0n ma n dc a p s o m e r sr a n g i n gf r o m8 - 1 0n mi n
diameter were also detected. Purified preparations of
chimeric proteins showed that ChiM2e2-24_c, ChiM2e2-
9_ c ,a sw e l la sC h i M 2 e 2-24_h4 successfully formed cap-
somers and VLPs of similar structure. On the contrary,
the chimeric construct with the M2e2-9 substitution in
h4 position (ChiM2e2-9_h4) formed only capsomers
(Figure 6).
Electron microscopy analysis confirmed the results of
the capture-ELISA obtained with conformation-specific
MAbs indicating the self-assembly of chimeric L1 pro-
tein in higher order protein structures (capsomers, T =
1 or T = 7 VLPs).
Discussion
The current study supports the possibility of using
plants as a method for the expression and folding of
proteins of human viruses and raises the prospect of
plants competing with other systems for the production
of low-cost and effective vaccines. In this work, we
Figure 2 Amino acid alignment of L1ΔC22 and chimeras. Structural helices and b-sheets are indicated as shadowed areas. M2e2-24
(SLLTEVETPTRNEWECKCIDSSD) or M2e2-9 (SLLTEVET) epitopes are shown in black areas.
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be successfully expressed in a transient manner in N.
benthamiana plants using a non replicating pEAQ-HT
expression vector; 2) the HPV-16 L1 carrier bearing the
M2e influenza epitope can be efficiently produced in
plants; 3) M2e influenza epitope presentation in either
h4 or h4-b-J coil positions is not detrimental for the for-
mation of capsomers and does not disrupt the recogni-
tion by conformation-dependent MAbs; 4) M2e epitopes
in coil position allow VLP formation; 5) M2e epitopes
in h4 position enable VLP assembly only when a longer
sequence of amino acids is used.
The HPV-16 L1 gene and chimeras were expressed in
plants using the small binary vector pEAQ-HT contain-
ing modified 5’-a n d3 ’-untranslated regions from Cow-
pea mosaic virus (CPMV) RNA-2, avoiding the double
cloning procedures necessary with standard binary vec-
tors with a concomitant saving in time. The successful
L1ǻC22 ChiM2 e2-24 h4 ChiM2e2-9 h4
A B C
L1ǻC22
ChiM2e2-9 c L1ǻC22 ChiM2e2-24 c
F D E
Figure 3 Three-dimensional structure of L1ΔC22 (aa. 46-500) and chimeric monomers.L 1 ΔC22 with marked (black) area within
manipulated h4 or h4-b-J coil structure, where the substitution with the influenza M2e epitope was done (A and D); chimeras with their
corresponding epitopes (in black) (B-C-E-F). Images A-B-C = structural modelling in h4; images D-E-F = structural modelling in the coil region.
For monomer visualization, 3D-Mol Vector NTI suite 9 application was used.
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erologous proteins in plants has been reported on sev-
eral occasions [32-34]. However, the size and complexity
of viral vector systems, as well as the genetic stability of
the constructs during viral genome replication and pos-
sible biocontainment issues can negatively affect their
widespread use, justifying the selection of non-replicat-
ing pEAQ-HT plasmid as a vector of choice for the cur-
rent studies.
The HPV-16 L1 protein carrier containing influenza
epitopes was expressed in plants, but the recognition of
M2e influenza sequences was achieved only in chimeras
Figure 4 Western blot analysis of leaf samples after infiltration with agrobacteria containing L1ΔC22 and the chimeric variants. (A) Anti
HPV16-L1 MAb MD2H11 was used at 1:5000 dilution. (B) Anti influenza Mab A M2 (14C2) was used at 1:1000 dilution. (C) Coomassie stained
Rubisco large subunit served as a loading control. Molecular markers are indicated on the right. M is a leaf tissue extract infiltrated with buffer
alone, used as a negative control.
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investigated if the lack of reaction with constructs carry-
ing the shorter version of the M2e influenza epitope is
due to the use of an inappropriate MAb or to epitope
inaccessibility on the carrier surface. So far, there is only
one report of the expression of a chimeric HPV16-L1
protein in transgenic plants, where the chimera was
made of L1 fused to E6/E7 epitopes of the same virus
[22]. Here we achieved for the first time the transient
expression in plants of chimeric HPV16-L1 bearing an
epitope of a heterologous virus, with a substitution
rather than a fusion strategy.
Several reports have demonstrated the usefulness of
the M2e as a means of inducing neutralizing antibodies
against influenza [35-37]. The N-terminus of M2e, con-
taining the highly conserved SLLTEVET epitope, com-
mon to both M1 and M2 proteins, was sufficient to
induce antibody production with an inhibitory effect
against this pathogen [38]. Two different versions of this
epitope were selected for the construction of HPV-chi-
meras. The major concern in introducing heterologous
epitopes into the L1 platform is to ensure their surface-
exposure while preserving the conformation of the L1
oligomer. HPV-16 pseudovirion infection is abolished by
the neutralizing MAbs V5 and E70 which recognize sur-
face exposed conformational epitopes of L1 [39]; these
epitopes are considered of crucial importance for immu-
nogenicity. All chimeric proteins tested in this work
reacted positively with a panel of linear and conforma-
tion-specific MAbs. Furthermore, the positive reaction
obtained with H16:V5 and H16:E70 indicated that both
epitopes inserted in either L1 positions preserved these
L1 immunogenic epitopes. Mab H16:D9 has affinity for
the denatured VLP antigen [28], and the weak binding
of L1ΔC22 and the chimeric proteins to this MAb
demonstrates that the assembled products are stable.
Electron microscopy results showed that the L1 pro-
tein purified by Cs2SO4 density gradient centrifugation
assembled into recognizable VLPs. Maclean et al. [14]
transiently expressed the L1 protein in the cytoplasm
and observed a size-range of the VLPs from 40-52 nm.
Our data are consistent with this work, and we found
VLPs ranging from 30-55 nm in the same plant host.
Chimeric particles with M2e substitutions in the coil
region predominantly assembled into T7 = VLPs. The
substitution of 14 aa of the L1 coil region with either 8
or 23 aa of the Influenza M2e region was not detrimen-
tal for VLP formation, thus confirming that this region
is not involved in the inter-pentameric reactions neces-
sary to create a VLP. The chimeric polypeptides having
shorter substitution in h4 (ChiM2e2-9_h4) could still
assemble into capsomers, but the formation of T = 1 or
T = 7 VLPs was inhibited, as expected on the basis of
the published crystal structure of HPV-16 L1 [10,11].
Interestingly, the substitution of the same h4 with a
Figure 5 Characterization of L1ΔC22 and chimeric variants expressed in N. benthamiana by capture-ELISA using linear and
conformation-specific MAbs. HPV-16 L1 VLPs derived from insect-cells were used as standard of known concentration (0.4 ng/μl). Absorbance
values refer to 2 h after substrate addition.
Table 2 Concentration of L1ΔC22 and chimeric proteins
Antigen Concentration in mg/kg
calculated by capture-ELISA
TSP (%)
H16:J4 H16:V5
L1ΔC22 79 43 2.5
ChiM2e2-24_h4 120 78 3.9
ChiM2e2-9_h4 38 36 1.4
ChiM2e2-24_c 45 45 1.5
ChiM2e2-9_c 29 31 0.9
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Page 7 of 12l o n g e rM 2 es e q u e n c e( C h i M 2 e 2-24_h4) allowed the
assembly into T = 1 and T = 7 VLPs, along with cap-
somer formation, indicating that the incorporation of a
longer version of the M2e epitope partially restored the
function of the deleted h4 region. This suggests that the
length of an epitope, as well as its amino acid sequence
is important for efficient VLP formation. Furthermore,
when h4 was substituted by a RSV epitope [21] or by a
Figure 6 Electron micrographs of purified bands from N. benthamiana leaf samples six days post-agroinfiltration with L1ΔC22 and
chimeric constructs. Black arrows = T7 VLPs of about 55 nm; grey arrows = T1 VLPs of about 30 nm; white arrows = capsomers. Assembled L1
structures for each constructs are enlarged on the right side. Bar = 50 nm.
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found assembled in preparations from insect cells sys-
tems. The detection of L1 superstructures for ChiM2e2-
24_h4 in plants suggests that the plant cell or the purifi-
cation strategy could additionally play important role in
HPV VLP formation/stability.
The yields reported in this work are in the range from
45 to 120 mg of total L1 protein per kg of fresh weight
for ChiM2e2-24_c and ChiM2e2-24_h4 (on the basis of
the linear H16:J4 MAb), thus fulfilling the often-
requested quantity for commercially viable production
of antibodies [15]. Previous works reported yields of L1
protein in N. benthamiana plants ranging from 40 μg
per kg of plant material with a transient expression sys-
tem of the native gene [40], to 533 mg per kg of plant
material in the case of a chloroplast-targeted L1 protein
transiently expressed from a human codon-optimized
gene, with a 5-fold decrease when the NLS was removed
(108 mg of L1ΔC22) [14]. Our yields of 79 mg for
L1ΔC22 and 120 mg for ChiM2e2-24_h4 are in accor-
dance with the highest yields reported so far for plant-
transiently expressed HPV-16 L1ΔC22. This approves
the use of L1 gene with the human codon preferences
and demonstrates the suitability of the pEAQ-HT vector
for HPV-16 L1 transient expression in plants. Further
enhancement of L1 yield could be obtained by appropri-
ately decreasing the GC content, and by deleting regions
prone to gene silencing, to reduce mRNA secondary
structure.
Three of the four chimeric proteins tested assembled
into VLPs and capsomers in plants, and one of them
produced only capsomers. VLP assembly in the three
chimeras emphasized their potential usefulness in future
immunogenicity studies; in fact, to achieve comparable
antibody responses at least 20 to 40 times more L1 are
required in the form of capsomeres than in the form of
VLPs [41]. Out of three VLP-forming chimeras,
ChiM2e2-24_h4 and ChiM2e2-24_c reacted also with anti-
influenza MAb, suggesting the availability of this epitope
on VLP surface. Considering that these two chimeras
had the highest L1 yield as well, we propose them as
candidate multivalent vaccines for further immunologi-
cal studies.
O u rw o r kd e m o n s t r a t e dt h a tc h i m e r i cH P V - 1 6L 1
proteins can be transiently expressed in plants in only
one week, with a significant-time reduction compared to
other plant-expression systems (transgenic or transplas-
tomic), thus offering new possibilities for rapid testing
of new chimeras made in plants.
T h eu s eo fas y n t h e t i cL1 gene designed to include
unique restriction sites opens further perspectives for
inserting other heterologous epitopes in different struc-
tural positions. Other interesting surface-exposed
regions are the D-E and F-G1 loops for which the
designed synthetic gene can be easily manipulated to
present single or multiple foreign epitopes. This syn-
thetic gene could also be used as a backbone for
exchanging longer portions of other HPV-16 or related
papillomavirus genes in order to synthesize novel vac-
cines with therapeutic and/or preventive use, or vaccines
with multiple features effective against more than one
papillomavirus.
Conclusions
The HPV-16 L1 protein was successfully expressed by
the CPMV-derived plant transient expression vector
pEAQ-HT. Chimeric constructs bearing a heterologous
influenza epitope were also successfully transiently
expressed in plants as judged by their reaction with
anti-HPV16 L1 specific MAbs. The characterization of
chimeras by electron microscopy showed appropriate
assembly of VLPs, with the exception of one chimera,
which formed only capsomers. Chimeras were recog-
nized by assembly-dependent conformation-specific
MAbs, confirming particle stability. The substitution of
the L1 h4 region with foreign epitopes of suitable size
had a positive impact on L1 self-assembly into VLPs,
compared to previous results showing that the deletion
of the same h4 region abolished VLP assembly. Interest-
ingly, this substitution had a positive effect on L1 yield,
too. Moreover, we designed a synthetic gene allowing an
easy manipulation of L1 structural positions suitable for
inserting exogenous sequences, thus opening new per-
spectives for a rapid and easy construction of different-
virus chimeras.
Methods
Gene synthesis and cloning
An HPV-16 L1 gene [GenBank:K02718] encoding the
native protein sequence lacking 22 aa at the 3’-terminus
was obtained by de novo synthesis from Geneart AG
(Regensburg, Germany). The sequence encoding
L1ΔC22 was optimized with human codon usage, and
provided with restriction sites necessary for further
cloning steps. The L1ΔC22 backbone gene was used to
design four chimeric variants bearing two M2e influenza
epitopes: M2e2-24 (SLLTEVETPTRNEWECKCIDSSD) or
M2e2-9 (SLLTEVET) inserted in place of the L1
sequence in h4 or the coil region (Table 1).
L1ΔC22 and chimeric genes were excised from the
pMK-RQ plasmid provided by GeneArt using the NruI
and XhoI restriction sites, and cloned in the correspond-
ing sites of the CPMV-derived binary expression vector
pEAQ-HT under the control of the Cauliflower mosaic
virus 35S promoter (kindly provided by G.P. Lomonoss-
off, John Innes Centre, Norwich, UK). Recombinant
plasmids were transformed into Escherichia coli DH5a
competent cells. The sequence of the resulting plasmids
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(Padova, Italy). Multiple sequence alignment of nucleo-
tide sequences (before and after synthesis) was done
using AlignX (Vector NTI Suite V 5.5, InforMax, North
Bethesda, Maryland) with the Clustal W algorithm [42].
Protein structure generation and analysis
Based on the pentameric protein model obtained from
HPV16-L1 T = 1 structure [PDB:1DZL], three-dimen-
sional structure modelling of L1ΔC22 and chimeric var-
iants was obtained using the 3D-JIGSAW Protein
Comparative Modelling Server [43] [http://bmm.cancer-
researchuk.org/~3djigsaw/]. 3D-Mol Vector NTI suite 9
application was used for protein visualization.
Agroinfiltration of L1ΔC22 and chimeric constructs
A. tumefaciens LBA4404 was transformed with the
plasmid pEAQ-HT containing L1ΔC22 and the four
chimeras. Agrobacterium cultures were grown for 2
days at 28°C in YEB medium containing kanamycin
(50 μg/ml) and rifampicin (50 μg/ml) and pelleted.
After resuspension in 10 mM MES 2-(N-morpholino)
ethansulfonic acid, pH 5.6, 10 mM MgCl2,a n d1 0 0
μM acetosyringone to an OD600 of 0.8 and 3 h incuba-
tion at room temperature, bacterial suspensions were
infiltrated into leaves of N. benthamiana plants. Con-
trol infiltration included the empty pEAQ-HT. Plants
were maintained in a growth chamber at 23°C (16:8 h
light:dark), and leaf tissue was collected six days after
agroinfiltration.
Protein extraction and analyses
Harvested agroinfiltrated tissue was ground in liquid
N2, homogenized in 9 volumes of Laemmli sample
buffer, and incubated at 100°C for 2 min. Extracts
were separated on 7.5% mini-protean TGX gel (Bio-
Rad, Richmond, CA) in Tris-glycine SDS-PAGE buf-
fer, and either stained with Coomassie brilliant blue
or electro-blotted to PVDF (polyvinylidene difluoride)
membranes (Millipore, Billerica, MA) using transfer
buffer (25 mM Tris, 192 mM glycine, 20% ethanol).
The membranes were incubated overnight at 4°C in
blocking solution (5% non-fat dry milk in PBS with
0.05% Tween-20), and incubated for 1 h at room tem-
perature with primary antibody. After washing with
PBS-0.05% Tween-20, the membranes were incubated
for 1 h at room temperature with an anti-mouse
horseradish peroxidase-conjugated secondary antibody
(Sigma-Aldrich, St. Louis, MO) at a 1:10000 dilution.
The reaction was detected with Supersignal West Pico
Chemiluminescent Substrate (Thermo Fisher Scienti-
fic, Rockford, IL).
TSP were measured by a Bradford assay (Bio-Rad) fol-
lowing manufacturer’s instructions.
Characterization of L1ΔC22 and chimeric constructs by
capture-ELISA
ELISA plates were coated overnight at 4°C with a 1:500
dilution of the anti-HPV-16 MAbs: H16:J4, H16:I23,
H16:V5, H16:E70, H16:U4, H16:9A, H16:D9, H16:7E
(kindly provided by N. Christensen, Pennsylvania State
University College of Medicine, Hershey, PA), then
washed and blocked with 5% milk PBS for 1 h at 37°C
in. Extracts of soluble proteins were prepared by homo-
genizing the agroinfiltrated leaves in 10 volumes of high
salt buffer (1× PBS, 0.5 M NaCl, 10 mM EDTA, 1 mM
PMSF buffer). Extracts were incubated for 1 h at 37°C,
followed by three washing steps. The 4543 polyclonal
antibody obtained against HPV-16 VLPs (kindly pro-
vided by M. Müller) was added at a 1:3000 dilution in
5% milk PBS for 1 h at 37°C. Following three washings,
the plates were incubated with an alkaline phosphatase-
conjugated goat anti-rabbit antibody (1:10000, Sigma-
Aldrich) for 1 h at 37°C. The reactions were detected
using p-nitrophenylphosphate( S i g m a - A l d r i c h ) ,a n d
absorbance of the reaction product measured at 405 nm
with an ELISA microplate reader (Bio-Rad, model 3550).
Insect cell-derived VLPs [41] of known concentrations
were used as standards.
Purification of L1ΔC22 and chimeric protein structures
VLPs and other higher order protein structures were
purified from leaves agroinfiltrated with L1ΔC22 and
chimeric constructs at six days post-agroinfiltration
using a protocol for begomovirus purification, essentially
as described by Luisoni et al. [31]. Harvested leaves were
ground with liquid N2, homogenized in 5 vol of extrac-
tion buffer (0.5 M PB, pH 6.0 containing antioxidants,
2.5 mM EDTA, 1% Triton X-100, and 0.1% Driselase),
and incubated overnight at 4°C. The homogenate was
emulsified with 15% chloroform and centrifuged for 15
min at 8,000 × g (Sorvall SS-34 rotor; Du Pont, CT).
The aqueous phase was collected and ultracentrifuged
for 2 h at 205,000 × g (Beckman 55.2 Ti rotor; Beckman,
CA). The resulting pellet was resuspended in 0.5 M PB
(pH 7.0) containing 2.5 mM EDTA and centrifuged for
15 min at 8,000 × g. The supernatant was collected and
loaded onto 20 to 50% Cs2SO4 density gradient in 0.5
M PB (pH 7.0) with 2.5 mM EDTA, and then subjected
to ultracentrifugation for 5 h at 160,000 × g (Beckman
SW41 rotor). Observed bands were collected, diluted in
0.1 M PB (pH 7.0), and ultracentrifuged for 40 min at
390,000 × g (Beckman TL100 rotor). Final pellets were
resuspended in 0.1 M PB (pH 7.0) for electron micro-
scopy observation.
Electron microscopy of purified protein products
For electron microscopy analysis, the above obtained
pelleted bands were adsorbed onto carbon-coated grid
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Page 10 of 12for approximately 1-3 minutes. Excess fluid was
removed with filter paper and the grids were negatively
stained with 0.5% uranyl acetate. The grids were then
observed and photographed using a CM 10 electron
microscope (Philips, The Netherlands).
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